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Aim: To evaluate the usefulness of visual and semiquantitative 18F-FDG PET-CT 
data for the diagnosis of a peri-anastomotic colorectal cancer recurrence taking 
into account the time period between the surgery and the 18F-FDG PET-CT 
scanning. 
Method: The study population consisted of 70 patients who had prior pre-
operative radiochemotherapy and surgical resection of the primary tumour and 
who underwent whole body 18F-FDG PET-CT scanning for the detection of 
recurrent disease. Visual and semiquantitative (SUVmax) analysis of the 
18F-FDG 
uptake at the peri-anastomosis was performed. The final diagnosis was based on 
pathological proof or clinical and/or imaging follow-up data. 
Results: On visual reading, 27 patients exhibited an increased 18F-FDG uptake at 
the peri-anastomosis. Of those, 11 (41%) patients had a local tumour recurrence 
and 16 (59%) patients had no recurrent tumour. Among 43 patients without 
increased 18F-FDG uptake at the peri-anastomosis, none had a local tumour 
recurrence. On semiquantitation, SUVmax in patients with and without a local 
recurrence overlapped. However, if the time period between the surgery and the 
18F-FDG PET-CT scanning was taken into account, overlap of SUVmax was 
mainly observed within a postoperative time period of ≤ 12 months. Thereafter, a 
threshold SUVmax of 3.2 discriminated between benign and malignant lesions in 
all but one patient.  
Conclusion: In our series, visually increased 18F-FDG uptake at the peri-
anastomosis was 100% sensitive but non-specific (specificity of 73%) for the 
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diagnosis of a local tumour recurrence. On the other hand, normal 18F-FDG 
uptake at the peri-anastomosis precluded a local tumour recurrence (negative 
predictive value of 100%). In addition, semiquantitative (SUVmax) analysis of the 
18F-FDG uptake at the peri-anastomosis may increase specificity (up to 97%), 
while preserving maximum sensitivity, if the postoperative time period is > 12 
months.  
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Surgical resection is the primary treatment modality for early stage colorectal 
cancer (CRC). Despite potentially curative surgery and the use of modern 
adjuvant chemotherapy and/or radiation therapy (RT), more than 40 percent of 
patients who present with stage II or III disease will have a disease recurrence 
following primary therapy, usually developing within 2 years of the primary 
surgery [1]. The most common metastatic sites are the regional lymph nodes, 
liver, lungs, and peritoneum [2]. After potentially curative resection of CRC, the 
purpose of surveillance is early identification of those patients who are potentially 
eligible for further curative therapy. Recent data support the view that intensive 
surveillance strategies improve survival because all forms of recurrences are 
detected early [3-5]. Furthermore, data supporting periodic imaging to detect 
early potentially resectable recurrences led the American Society of Clinical 
Oncology (ASCO) to reverse its previous recommendation against including CT 
scans as a component of the post-treatment surveillance strategy in 2005 [6].  
Because of the high 18F-fluorodeoxyglucose (18F-FDG) uptake in primary 
colorectal carcinomas and their recurrences, 18F-FDG PET or combined 18F-FDG 
PET-CT that allows identification of increased glucose metabolism by PET with 
the display of the underlying anatomy by CT may also have a role in the 
evaluation of colorectal cancer recurrence (CRCR) [7,8]. However, the 
differentiation between local CRCR and changes attributable to previous surgery 
and/or radiotherapy often constitutes a major diagnostic challenge [9]. Because 
of the well-known 18F-FDG uptake associated with inflammatory lesions [10], 
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evaluation of the anastomosis, the stoma, the post-operative abdominal wall and 
the port sites after laparoscopic surgery may be difficult [11]. Moreover, the CT 
scan may not be very helpful in these cases because there are often no 
morphological changes associated with focal inflammation [12].  
The aim of this retrospective study was to investigate the usefulness of visual 
and semiquantitative 18F-FDG PET-CT data for the diagnosis of a peri-
anastomotic colorectal cancer recurrence taking into account the time period 
between the surgery and the 18F-FDG PET-CT scanning.  
 
Patients and Methods 
Patients 
For this retrospective study, the study population consisted of 70 patients (43 
men and 27 women) who underwent whole body 18F-FDG PET-CT scanning at 
our institution. All had prior pre-operative radiochemotherapy (total dose of 45 Gy 
in 25 fractions; 1.8 Gy per fraction; in combination with 5-fluorouracil during the 
first and the fifth week). Surgery was performed 6 weeks after the end of the 
radiotherapy course. 18F-FDG PET-CT scanning was performed at different time 
points after surgery (mean ± standard deviation, 26 months ± 20; range, 0-88 
months). Indications for PET-CT scanning were an unexplained increase in 
carcinoembryonic antigen (CEA) values (n=39), suspected intra- or extra-
abdominal tumour recurrence based on abnormal findings on CT or other 
imaging modalities (n=19), restaging prior to surgical removal of presumably 
resectable liver metastasis (n=4), monitoring of therapy (n=4) and staging of a 
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second primary tumour (n=4). None of these patients had inflammatory bowel 
disease, post-operative and/or radiotherapy-induced complications, such as 
fistula, abscess or retroperitoneal fibrosis. 
 
18F-FDG PET-CT scanning 
All examinations were performed according to the standard protocol at the Ghent 
University Hospital. The patients fasted at least 4 hours prior to intravenous 
injection of 18F-FDG (3.7 MBq/kg body weight). Blood glucose levels were 
checked prior to the injection of 18F-FDG and did not exceed 140 mg/dL. 
Iodinated intravenous contrast (Iohexol (Omnipaque) 300 or iomeprol 
(Iomeron) 400) was administered immediately before the CT scanning. 
Iodinated oral contrast material was not administered and patients who had 
undergone a CT examination with iodine-based peroral contrast medium for the 
opacification of the bowel within 1 week of the PET-CT scanning were excluded 
from the study. Patients were imaged with the Gemini PET-CT imaging system 
(Philips Co., Cleveland, USA), which consists of a gadolineum oxyorthosilicate 
(GSO) full-ring PET scanner with 5.0 mm spatial resolution and a 16-slice helical 
CT scanner. After a 60-min uptake period, during which patients were instructed 
to rest silently, images were acquired. First, a CT surview (30 mA, 120 kV, FOV 
500 mm, collimation 0.75 mm) was performed from the base of the skull through 
the mid thigh. This was followed by a low-dose CT (30 mA, 120 kV, FOV 600 
mm, 0.5 s rotation time, pitch 0.9, collimation 16 × 1.5 mm) and a high-quality CT 
(150 mA, 120 kV, FOV 500 mm, 0.5 s rotation time, pitch of 0.9, collimation 16 × 
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1.5 mm, slice thickness and increment 5 mm) without specific breath-holding 
instructions and arms at the side of the torso. PET scanning was performed 
immediately after acquisition of the CT images, without changing the patient 
position. Between 5 and 8 bed positions were used, with an acquisition time of 3 
min per bed position. PET images were reconstructed by using an iterative 3D-
RAMLA (Row Action Maximum Likelihood Algorithm) algorithm provided by 
Philips. Low-dose CT data were used for attenuation correction.  
 
Image analysis 
Images were interpreted at a workstation equipped with fusion software 
(Syntegra, version 2.1E, Philips) that enables the display of CT, PET and PET-
CT images. In keeping with the purpose of this study, visual and semiquantitative 
assessment of the 18F-FDG uptake was focused on the peri-anastomotic region 
that was defined on the CT part of the integrated PET-CT images (see below). 
Combined PET-CT images were interpreted in a consensus reading by two 
observers who were blind to the clinical findings. Other intra- and extra-
abdominal sites with increased 18F-FDG uptake were also recorded, but they 
were not included in the analysis of the results.  
The procedure for the semiquantitative assessment of the 18F-FDG uptake at the 
peri-anastomotic region was divided into the following steps: axial CT slices of 
the PET-CT images were used to identify the suture line. The peri-anastomotic 
region was defined as the CT volume that contained all continuous axial slices 
(range 2-10) in which radio-opaque suture material could be visualized and an 
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additional, arbitrarily chosen, 10 slices (or 50 mm) proximal and distal of the 
suture line. This was done because only a few local recurrences are primarily 
anastomotic, occurring at the suture line [13]. Subsequently, the SUVmax in this 
volume was calculated on the co-registered attenuation corrected PET images. 
This parameter reflected the ratio of the activity in tissue per millilitre to the 
activity in the injected dose per patient body weight in kilograms.  
 
Data analysis 
In patients with visually increased 18F-FDG uptake, the final diagnosis was based 
on pathological proof obtained by colonoscopy and/or laparotomy. In patients 
with normal 18F-FDG uptake at the peri-anastomosis, the final diagnosis was 
given by clinical and/or imaging follow-up data during at least 24 months after 
surgery (mean ± SD, 56 months ± 23, range, 25-115). The local ethics committee 
approved the retrospective analysis of patient files and images. 
 
Results 
Of the 70 patients included in this study (mean age ± SD, 65 years ± 9; range, 
46-80 years), 43 were men (mean age 67 years ± 7), and 27 were women (mean 
age 62 years ± 10). Patient characteristics are described in Table 1. Of these 
patients, 59 had no local tumour recurrence and 11 patients had evidence of a 
recurrent tumour. On visual reading, 27 patients exhibited an increased 18F-FDG 
uptake at the peri-anastomosis. Of those, 11 (41%) patients had a local tumour 
recurrence, whereas 16 patients (59%) had no recurrent tumour. However, 
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recurrent disease in other locations was frequently recorded. Among 43 patients 
without increased 18F-FDG uptake at the peri-anastomosis, none had a tumour 
recurrence (see also Table 2).  
On semiquantitation of the 18F-FDG uptake, SUVmax in patients with and without 
a local recurrence overlapped (see Figure 1). However, if the time period 
between the surgery and the 18F-FDG PET-CT scanning was taken into account, 
overlap of SUVmax was observed mainly within a postoperative period of ≤ 12 
months (see also Figure 2). Thereafter, a threshold SUVmax of 3.2 discriminated 
between benign and malignant lesions in all but one patient (see also Figure 2). 
Colonoscopy in this patient was negative for malignancy. 
 
Discussion 
PET imaging using 18F-FDG is well accepted in the imaging work-up of various 
malignancies. PET is recognized as a useful tool to manage colorectal cancer 
and was shown to have an additional value in the detection of CRCR [14,15]. 
The overall accuracy of PET may further be increased by using the integrated 
PET-CT imaging modality, which combines the benefits of PET with those of 
anatomical imaging [9,12,16]. However, the differentiation between local CRCR 
and benign changes associated with previous surgery and/or radiotherapy often 
remains challenging [9]. Our findings agree with those in the literature in that we 
found that visual reading on PET was 100% sensitive (11 patients with a 
recurrent tumour had increased 18F-FDG uptake at the peri-anastomosis 
(100%)), but non-specific for the diagnosis of a peri-anastomotic CRCR (16 out 
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of 27 patients (59%) with visually increased 18F-FDG uptake at the peri-
anastomosis had no recurrent tumour). This result may be explained, at least 
partly, by the fact that visual analysis is heavily dependent on observer 
experience and training and lacks a clearly defined cut-off to distinguish between 
normal and pathological findings. We therefore hypothesized that semi-
quantitative measurement of local 18F-FDG uptake might increase specificity. 
However, on semiquantitation, SUVmax in patients with and without a local 
recurrence overlapped (see also Figure 1). Thus, our findings seem not to 
support the usefulness of quantifying 18F-FDG uptake. This is in line with other 
findings in the literature [9,17]. In the report by Delbeke et al. [17], the authors 
investigated the role of 18F-FDG PET in the staging of recurrent CRC based on a 
visual interpretation of CT and 18F-FDG PET images. The authors also 
investigated whether the standard uptake ratio (SUR) could be used to 
discriminate malignant from benign lesions. SUR was calculated as the ratio of 
the activity in the region of interest drawn over the areas of maximal activity per 
millilitre to the activity in the injected dose per patient body weight in kilograms. 
They found that SUR was useful in differentiating malignant from benign lesions 
in the liver, but that SUR was not useful for the identification of extrahepatic 
recurrent disease because physiological bowel uptake could not reliably be 
discriminated from tumour recurrence. In a more recent report, Even-Sapir et al. 
[9] investigated the role of combined 18F-FDG PET-CT in the evaluation of pelvic 
tumour recurrence in patients who had undergone surgery for rectal cancer, 
based on visual interpretation of the PET-CT images. In addition, they 
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investigated the potential value of the maximal standard 18F-FDG uptake 
(SUVmax) as a semiquantitative parameter to differentiate pelvic tumour 
recurrence from benign pelvic lesions. They found that the average SUVmax of a 
tumour recurrence was not significantly different from the average value of non-
tumoural pelvic lesions. However, it may be argued that the discriminatory power 
of SUVmax measurements may be enhanced by taking the postoperative time 
period into account. We found that a threshold SUVmax of 3.2 discriminated 
between malignant and benign changes in all but one patient, if the postoperative 
time period was > 12 months (specificity of 97%). Contrarily, within 12 months 
postoperatively, the use of 18F-FDG PET for the detection of a peri-anastomotic 
tumour recurrence warrants caution (specificity of only 80%). It is well known that 
false-positive cases are most likely due to inflammatory changes that have 
increased 18F-FDG uptake [18], and therefore can be mistaken for tumour 
recurrence. After a postoperative time period of > 12 months, increased 18F-FDG 
uptake at the peri-anastomosis corresponded with a tumour recurrence, although 
we cannot explain the finding of increased 18F-FDG uptake (SUVmax 3.9) in a 
case without a recurrent tumour 57 months postoperatively (see also Figure 3).  
The threshold SUVmax value of 3.2 should be considered with caution, as the 
number of subjects in this study was limited and the optimal value of the 
threshold may vary for different patient populations. Moreover, recent studies 
have shown that SUV measures depend on camera type and on acquisition and 




Normal 18F-FDG uptake at the peri-anastomosis is highly specific for the absence 
of a local CRCR (negative predictive value of 100%). On the other hand, visually 
increased 18F-FDG uptake at the peri-anastomosis can correspond to a tumour 
recurrence or to postoperative inflammatory changes. SUVmax measurements 
might help to further discriminate between benign and malignant lesions, if the 
postoperative time period is > 12 months. Based on our findings, a threshold 
SUVmax of 3.2 may be proposed. Further studies are needed to confirm the 
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Table 1: Patient characteristics, tumour stage, and indications for PET-CT in patients 
with colorectal cancer .  
 
Total number of patients 70 
Gender (n) men 43 
women 27 
Age (years, mean ± SD) 65  ± 9 
Primary tumour site sigmoid 46 
rectum 24 
Tumour stage at diagnosis I 8 
 IIA 12 
 IIB 3 
 IIIA 9 
 IIIB 20 
 IV 18 
Indication for PET-CT scanning elevated CEA 39 
 suspected tumour recurrence, anywhere 19 
 evaluation resectability of liver mets 4 
 therapy response  4 
 staging second primary tumour 4 
Postoperative delay 1-12 months 24 
 12-24 months 16 








Table 2: Visual analysis of the 18F-FDG uptake at the peri-anastomosis in 





(histology as the gold 
standard) 
no tumour recurrence 
(histology and/or follow-
up information as the 
gold standard) 
 
increased  11 16 27 
normal  0 43 43 






Figure 1: scatter plot of SUVmax showing overlap between patients with (R+) and without 












Figure 2: Two-dimensional representation of SUVmax at the peri-anastomosis after 
surgery in patients with and without a tumour recurrence showing overlap of SUVmax 
between benign and malignant lesions within 12 months postoperatively. Thereafter, a 
threshold SUVmax of 3.2 (dotted line) discriminated between inflammation and tumour 








Figure 3:  
Representative CT and PET images of the case with the lowest SUVmax value for a 
proven tumour recurrence at 14 months postoperatively (upper row) and the single false 
positive case at 57 months postoperatively (lower row).  
Upper row: Transaxial CT image (left) showing asymmetric thickening of the bowel wall 
at the perianastomotic region. Focally enhanced 18F-FDG uptake on the corresponding 
transaxial PET image (middle). SUVmax (=3.264) was just above the threshold value. 
Visualization of the radio-opaque suture material on the corresponding sagittal CT image 
(right).  
Lower row: On the transaxial CT image (left) radio-opaque suture material is visible at 
the normal anastomosis. Increased 18F-FDG uptake is noted on the corresponding 
transverse (middle) and sagittal (right) PET image. SUVmax (= 3.937) was above the 
threshold value. Colonoscopy in this patient was negative for malignancy.  
 
 
 
 
